Solifenacin significantly improves all symptoms of overactive bladder syndrome (Q30445725)

6 September 2017

4 references

22 April 2019

17 September 2019

2 October 2019

14 July 2021

0 references

Solifenacin significantly improves all symptoms of overactive bladder syndrome (English)

1 reference

6 September 2017

low compliance bladder

4 references

22 April 2019

17 September 2019

2 October 2019

29 May 2020

heterocyclic compound

1 reference

17 September 2019

1 reference

2 October 2019

tetrahydroisoquinolines

1 reference

14 July 2021

Christopher R Chapple

series ordinal

1

1 reference

6 September 2017

Cardozo L

2

1 reference

6 September 2017

Steers WD

series ordinal

3

1 reference

6 September 2017

Govier FE

series ordinal

4

1 reference

6 September 2017

1 August 2006

6 references

International Journal of Clinical Practice

6 September 2017

22 April 2019

17 September 2019

2 October 2019

29 May 2020

14 July 2021

5 references

6 September 2017

22 April 2019

17 September 2019

2 October 2019

14 July 2021

60

1 reference

6 September 2017

8

1 reference

6 September 2017

959-966

1 reference

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Antimuscarinics for treatment of overactive bladder

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Diagnosis and treatment of the overactive bladder

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial

20 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2006.01067.X

Improved quality of life in patients with overactive bladder symptoms treated with solifenacin

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Standardization of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the Standardisation Committee of the International Continence Society.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

Economic considerations and outcome measurement in urge incontinence.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1619936

How much is enough and who says so?

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16893438

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1742-1241.2006.01067.X

1 reference

release_mwopegxm5rbr5ecjzdm3txua44

6 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mwopegxm5rbr5ecjzdm3txua44

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

6 September 2017

PubMed publication ID

16893438

1 reference